Orchestra Biomed Highlights Pivotal Hypertension and Artery Disease Therapies in New Corporate Presentation
I'm PortAI, I can summarize articles.
Orchestra Biomed Holdings Inc. has unveiled a corporate presentation detailing its pivotal-stage medical therapies for hypertension and artery disease. The company is advancing its AVIM Therapy for high blood pressure and the Virtue SAB for atherosclerotic artery disease, with ongoing pivotal trials. Recently, Orchestra Biomed raised over $147 million to support development through late 2027, targeting significant market opportunities exceeding $17 billion for hypertensive heart disease and $10 billion for atherosclerotic artery disease.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments